BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1530 related articles for article (PubMed ID: 32179290)

  • 1. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
    Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
    J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
    Pickhardt PJ; Correale L; Hassan C
    AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 12. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
    Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
    Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel multitarget stool DNA test for colorectal cancer screening.
    Malik P
    Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
    Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
    Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
    Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
    Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
    Berger BM; Schroy PC; Dinh TA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
    Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
    J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal DNA Testing for Colorectal Cancer Screening.
    Carethers JM
    Annu Rev Med; 2020 Jan; 71():59-69. PubMed ID: 31451044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive fecal testing for colorectal cancer.
    Zou J; Xiao Z; Wu Y; Yang J; Cui N
    Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.